Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) EBIT Margin (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBIT Margin for 15 consecutive years, with 420.04% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 14384.0% to 420.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 293.46% through Dec 2025, down 4114.0% year-over-year, with the annual reading at 293.46% for FY2025, 4114.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 420.04% at Plus Therapeutics, down from 320.83% in the prior quarter.
  • The five-year high for EBIT Margin was 1508.19% in Q3 2021, with the low at 6978.08% in Q3 2022.
  • Average EBIT Margin over 5 years is 665.7%, with a median of 276.2% recorded in 2024.
  • The sharpest move saw EBIT Margin plummeted -848627bps in 2022, then soared 690420bps in 2023.
  • Over 5 years, EBIT Margin stood at 1508.19% in 2021, then crashed by -391bps to 4387.4% in 2022, then skyrocketed by 93bps to 293.83% in 2023, then grew by 6bps to 276.2% in 2024, then crashed by -52bps to 420.04% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 420.04%, 320.83%, and 110.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.